NASDAQ:NKTR

Nektar Therapeutics Stock News

etoro logo Buy NKTR
*Your capital is at risk
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Bank of New York Mellon Corp boosted its stake in Nektar Therapeutics (NASDAQ:NKTR) by 23.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commis
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Revance Therapeutics (RVNC), with a price target of $35.00. The
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Revance Therapeutics ( RVNC – Research Report ), with a price target of $35.00 . The company’s shares close
Medicenna's IL-2 Superkine, MDNA19, released recent data from non-human primate study suggesting best-in-class features. The small pilot study in monkeys showed
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT), with a price target of $183.00. The
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics ( SRPT – Research Report ), with a price target of $183.00 . The company’s shares clos

's Top Upgrades, Downgrades For March 30, 2020

01:35pm, Monday, 30'th Mar 2020
Upgrades Cowen & Co. changed the rating for Cerner Corp (NASDAQ: CERN) from Market Perform to Outperform. Cerner earned $0.75 in the fourth quarter, compared...
Monday's top analyst upgrades and downgrades included Alphabet, Amazon.com, Amgen, Cerner, eBay, Gap, Nike, Nucor, Procter & Gamble, TJX and ViacomCBS.
BioSig Technologies (NASDAQ:BSGM) initiated with Buy rating and $9 (75% upside) price target at Roth Capital.Amgen (NASDAQ:AMGN) upgraded to Outperform with a $255 (29% upside) price target at Raymond
Goldman Sachs analyst Paul Choi upgraded Nektar Therapeutics to Neutral from Sell with a price target of $20, up from $18.
Nektar upgraded to Neutral from Sell at Goldman Sachs Goldman Sachs NKTR
Nektar Therapeutics (NASDAQ:NKTR) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Monday, BidAskClub reports
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE